Deforestation Drives Disease, Climate Change and It’s Happening at a Rapid Rate

Deforestation is not an issue dominating headlines in the U.S. right now, but perhaps it should be, according to UC San Diego research. Deforestation has been linked to both the spread of infectious disease and climate change, and what is most alarming, it’s happening at a rapid rate.

Read more

The PALM Trial honored with the Society for Clinical Trials’ prestigious David Sackett Trial of the Year Award for 2020

Each year since 2008, SCT has awarded the David Sackett Trial of the Year Award to a randomized, controlled trial published (either electronically or in print) in the previous calendar year. The 2020 recipient is Pamoja Tulinde Maisha (PALM [“Together Save Lives”] in the Kiswahili language) trial.

Read more

Repeated novel coronavirus media exposure may be linked to psychological distress

Irvine, Calif., March 23, 2020 – While government officials and news organizations work to communicate critical risk assessments and recommendations to the public during a health crisis such as the new coronavirus pandemic, a related threat may be emerging, according to researchers at the University of California, Irvine: psychological distress resulting from repeated media exposure to the crisis.

Read more

Researchers Show How Ebola Virus Hijacks Host Lipids

Robert Stahelin studies some of the world’s deadliest viruses. Filoviruses, including Ebola virus and Marburg virus, cause viral hemorrhagic fever with high fatality rates. Stahelin, professor at Purdue University, examines how these viruses take advantage of human host cells.

Read more

Texas Biomed continues testing Ebola therapies and vaccines showing promise in outbreak areas

In mid-August 2019, human clinical trials were halted in the current Ebola epidemic that has claimed more than 2,100 lives in Africa. The findings resulted in the discontinuation of two of the drugs in the trial. Future patients will be randomly assigned to receive either REGN-EB3 (Regeneron) or mAb114 (Ridgeback Biotherapeutics) in an extension phase of the study. Texas Biomedical Research Institute scientists in the Institute’s Biosafety Level 4 contract research program conducted preclinical testing of several of the compounds in the trial, working with Regeneron and the Biomedical Advanced Research and Development Authority (BARDA).

Read more